GlobeNewswire - Industry News on Health Care

BBS-Bioactive Bone Substitutes Plc: Financial Statements Review 1.1.-31.12.2020 (unaudited)

Wed, 24 Feb 2021 17:15 GMT

Financial statement release on 24 February 2021 at 7:15 p.m. (CET)

BBS-Bioactive Bone Substitutes Oyj: Tilinp??t?stiedote 1.1.2020 - 31.12.2020 (Tilintarkastamaton)

Wed, 24 Feb 2021 17:15 GMT

BBS-Bioactive Bone Substitutes Oyj: Tilinp??t?stiedote 1.1.2020 - 31.12.2020 (Tilintarkastamaton)

Dr Manola: cosmetic surgery procedures increased during pandemic

Wed, 24 Feb 2021 17:10 GMT

Self-care while wearing face masks

Self-care while wearing face masks

RAMSAY SANTE : Half-year Results at the end of December 2020

Wed, 24 Feb 2021 16:35 GMT

???????????

RAMSAY SANTE : résultats semestriels à fin décembre 2020

Wed, 24 Feb 2021 16:35 GMT

COMMUNIQUé DE PRESSE
Paris, le 24 février 2021

LIDDS files patent application for method to treat brain cancer with intratumoral depot injections

Wed, 24 Feb 2021 16:19 GMT

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid? for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site.

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Wed, 24 Feb 2021 16:01 GMT

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions:

Indberetning af ledelsens transaktioner med ALK-Abelló A/S'?B-aktier og tilknyttede v?rdipapirer

Wed, 24 Feb 2021 16:01 GMT

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) indberetter hermed f?lgende transaktioner:

Cybrexa Therapeutics与美国国家癌症研究所签订合作研发协议（CRADA）以开发CBX-12（alphalex?- exatecan）

Wed, 24 Feb 2021 15:38 GMT

- Cybrexa与NCI将合作开发Cybrexa的主要候选药物CBX-12，以评估对实体肿瘤患者的安全性和疗效 -

Allarity Therapeutics Provides Update on Pre-Clinical Testing of Stenoparib’s Antiviral Activity Against New Variants of Coronavirus

Wed, 24 Feb 2021 15:19 GMT

Press Release ????

Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome

Wed, 24 Feb 2021 15:00 GMT

VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical?company focused on?chronic inflammatory?and autoimmune diseases,?is pleased to announce that?one of its drugs?produced?strong effects?in modulating gut microbiota?in a mouse model study of?inflammatory bowel disease.?In a study run by the?Gut4Health Microbiome Core?at?BC’s Children’s Hospital Research Institute,?the?compound?induced?a?distinct?shift in?microbiota composition, by increasing?“good” bacteria?while?suppressing?bacteria?associated with?the development?of?obesity?and?type 2?diabetes.?Particularly exciting was the finding that our compound induced a substantial increase in the species Akkermansia?muciniphila, a bacterium?shown to elicit?a wide range of?positive health benefits,?including reduced?obesity and systemic inflammation, and improved?gut barrier function.?Chronic?diseases driven by?obesity and?obesity-related?conditions?accounted for?over?$480 billion?USD?in direct health care costs?in the U.S.?alone?(2016).?

22nd Century Group Provides Business Update Letter from CEO

Wed, 24 Feb 2021 15:00 GMT

Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis

Global Commercial Opportunities in Approximately +$800 Billion Markets Across Tobacco and Hemp/Cannabis

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

Wed, 24 Feb 2021 14:35 GMT

EAST SETAUKET, NY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual H.C. Wainwright Global Life Sciences Conference, being held March 9-10, 2021.?Investors may register and consult the conference agenda at the event website.

AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

Wed, 24 Feb 2021 14:15 GMT

OCALA, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.

Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine? Development Program

Wed, 24 Feb 2021 14:15 GMT

MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)? (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered with a gene from the human immune system called the DR4 human leukocyte antigen (HLA) allele, which is one of hundreds of alleles in the human immune system. HLAs?are proteins - or markers -found on most cells in your body. Your immune system uses these markers to recognize which cells belong in your body and which do not. So, for example, HLA is used to match patients and donors for bone marrow or organ transplants. The Ii-Key is specific for human HLA, so therefore does not work in other species, making it difficult to evaluate vaccine efficacy in animal models. The DR4 transgenic mouse provides an opportunity to evaluate the ability of Ii-Key vaccines to generate immune responses in an animal model, recognizing that the DR4 allele is only one of dozens of human HLA epitopes contained in the Ii-Key-SARS-CoV-2 vaccine.

CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors

Wed, 24 Feb 2021 14:00 GMT

DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, today announced the appointment of Dr. Edgardo Baracchini, to the Company’s board of directors.

Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy

Wed, 24 Feb 2021 14:00 GMT

Phase 1b trial demonstrates that the company’s lead precision medicine asset is safe and well tolerated

Phase 1b trial demonstrates that the company’s lead precision medicine asset is safe and well tolerated

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Wed, 24 Feb 2021 14:00 GMT

TORONTO and CHICAGO and MONTREAL, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)?today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along with its MD&A post market on March 1, 2021.

Nass Valley Gateway Ltd (NVG) Announces It Has Retained Former Kannaway CEO Jeff Rogers as Consultant

Wed, 24 Feb 2021 14:00 GMT

?ROGERS WILL DESIGN AND LEAD THE ROLLOUT OF NVG’s PROPRIETARY “NASS VALLEY DIRECT” SALES CHANNEL

Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data

Wed, 24 Feb 2021 14:00 GMT

Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review

Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review